Transcranial Magnetic Stimulation for Alzheimer's Disease Treatment

Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age60-75
SponsorUniversitat Oberta de Catalunya

About this trial

Background: Alzheimer's disease is a major health problem in our society. To date, pharmacological treatments to reduce Alzheimer's disease symptoms have obtained poor results and there is a growing interest in finding non-pharmacological treatments for this impactful disease. Transcranial Magnetic Stimulation is a non-invasive tool which can induce changes in brain activity and long term modifications of impaired neural networks, and therefore holds promise as a clinical intervention.

Our overall goal is to study the benefit of targeting Transcranial Magnetic Stimulation based on the individual's unique functional connectivity (personalized targeting) instead of current non-individualized approaches. Specifically, the intermittent Theta Burst protocol will be used and changes in cognitive, functional, and emotional deficits in these patients will be evaluated. Functional brain connectivity changes induced by the TMS treatment will be also assessed.

Methods: A double blind randomized controlled trial will be conducted to assess the effects of TMS treatment immediately, one month, three months and six months after the end of the treatment in comparison to the baseline measurements. Forty-five patients with a diagnosis of Alzheimer's disease, will be randomly allocated (1:1:1) into experimental (active Transcranial Magnetic Stimulation), sham control group, or conventional intervention control group. Neuropsychological, functional, and emotional assessment will be conducted, as well as functional connectivity measures, in order to assess the effectiveness of the treatment.

Discussion: The investigators expect to demonstrate that personalized Transcranial Magnetic Stimulation intervention has measurable positive impact in cognitive and emotional functioning, functionality, and brain connectivity, thus representing a potential treatment for Alzheimer's disease.

Eligibility criteria

Qualifiers

Diagnosis of Alzheimer's disease according to the diagnostic criteria of the National Institute on Ageing and the Alzheimer's Association

Ages between 60 and 75 years

Mini Mental State Examination score between 20 and 26

Global Deterioration Scale score of 3 or 4

Disqualifiers

Knowledge of Spanish or Catalan after the age of 15

Less than 4 years of schooling

Intellectual deficiency (Premorbid Intelligence Quotient, vocabulary, less than 85)

Not controlled medical conditions or severe mental disorders that may affect the Central Nervous System, including signs of increased intracranial pressure or intracranial lesions

Trial design

Treatments tested in this trial

  • Active Transcranial Magnetic Stimulation
  • Sham Transcranial Magnetic Stimulation

Treatment groups

45 Participants
are divided into 3 treatment groups

Locations

This trial has no locations

Sponsors and collaborators

Universitat Oberta de Catalunya

Lead sponsor

Consorci Sanitari de Terrassa

Collaborator